IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy

Journal of Infection

Volumn 70, Issue 4, 2015, Pages 381-391

  Wergeland, I ^a   Pullar, N ^b,c   Assmus, J ^d   Ueland, T ^e,f   Tonby, K ^e   Feruglio, S ^e   Kvale, D ^e,g   Damas J K ^h,i   Aukrust, P ^e,f,g   Mollnes, T E ^e,h,j   Dyrhol Riise, A M ^a,e,g  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^j NORDLAND HOSPITAL   (Norway)

more..

Author keywords

Biomarker; Cytokines; HIV; IP 10; STNFr2; Therapy; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR RECEPTOR 2; BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON;

ADULT; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DOWN REGULATION; DRUG MONITORING; ENZYME IMMUNOASSAY; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SHORT COURSE THERAPY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; AGED; BLOOD; COMPLICATION; IMMUNOASSAY; MIDDLE AGED; MIXED INFECTION; TUBERCULOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHEMOKINE CXCL10; COINFECTION; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOASSAY; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; YOUNG ADULT;

EID: 84926086743     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.12.019     Document Type: Article

References (53)

1. World Health Organization Global tuberculosis report 2014, Available:, [accessed 12.12.14]. http://www.who.int/tb/publications/global_report/en/.
2. Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989 Mar 2, 320(9):545-550.
3. Pai M., Denkinger C.M., Kik S.V., Rangaka M.X., Zwerling A., Oxlade O., et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014 Jan, 27(1):3-20.
4. Parida S.K., Kaufmann S.H. The quest for biomarkers in tuberculosis. Drug Discov Today 2010 Feb, 15(3-4):148-157.
5. Chiappini E., Fossi F., Bonsignori F., Sollai S., Galli L., de M.M. Utility of interferon-gamma release assay results to monitor anti-tubercular treatment in adults and children. Clin Ther 2012 May, 34(5):1041-1048.
6. Holtz T.H., Sternberg M., Kammerer S., Laserson K.F., Riekstina V., Zarovska E., et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006 May 2, 144(9):650-659.
7. Wallis R.S., Wang C., Doherty T.M., Onyebujoh P., Vahedi M., Laang H., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2010 Feb, 10(2):68-69.
8. Benator D., Bhattacharya M., Bozeman L., Burman W., Cantazaro A., Chaisson R., et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002 Aug 17, 360(9332):528-534.
9. Johnson J.L., Hadad D.J., Dietze R., Maciel E.L., Sewali B., Gitta P., et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009 Sep 15, 180(6):558-563.
10. Biselli R., Mariotti S., Sargentini V., Sauzullo I., Lastilla M., Mengoni F., et al. Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clin Microbiol Infect 2010 Aug, 16(8):1282-1284.
11. Chegou N.N., Black G.F., Kidd M., van Helden P.D., Walzl G. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009, 9:21.
12. Chegou N.N., Detjen A.K., Thiart L., Walters E., Mandalakas A.M., Hesseling A.C., et al. Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting. PLoS One 2013, 8(5):e64226.
13. Frahm M., Goswami N.D., Owzar K., Hecker E., Mosher A., Cadogan E., et al. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb ) 2011 May, 91(3):250-256.
14. Mihret A., Bekele Y., Bobosha K., Kidd M., Aseffa A., Howe R., et al. Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect 2013 Apr, 66(4):357-365.
15. Sutherland J.S., de Jong B.C., Jeffries D.J., Adetifa I.M., Ota M.O. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One 2010, 5(8):e12365.
16. Chegou N.N., Heyckendorf J., Walzl G., Lange C., Ruhwald M. Beyond the IFN-gamma horizon: biomarkers for immunodiagnosis of infection with M. tuberculosis. Eur Respir J 2014 May, 43(5):1472-1486.
17. Ruhwald M., Aabye M.G., Ravn P. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev Mol Diagn 2012 Mar, 12(2):175-187.
18. Goletti D., Raja A., Syed Ahamed K.B., Rodrigues C., Sodha A., Carrara S., et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?. PLoS One 2010, 5(9):e12577.
19. Kabeer B.S., Sikhamani R., Raja A. Comparison of interferon gamma and interferon gamma-inducible protein-10 secretion in HIV-tuberculosis patients. AIDS 2010 Jan 16, 24(2):323-325.
20. Vanini V., Petruccioli E., Gioia C., Cuzzi G., Orchi N., Rianda A., et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 2012 Jul, 65(1):49-59.
21. Alsleben N., Ruhwald M., Russmann H., Marx F.M., Wahn U., Magdorf K. Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study. Scand J Infect Dis 2012 Apr, 44(4):256-262.
22. Latorre I., Diaz J., Mialdea I., Serra-Vidal M., Altet N., Prat C., et al. IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children. J Infect 2014 Dec, 69(6):590-599.
23. Lighter J., Rigaud M., Huie M., Peng C.H., Pollack H. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int J Tuberc Lung Dis 2009 Jun, 13(6):731-736.
24. Ruhwald M., Petersen J., Kofoed K., Nakaoka H., Cuevas L.E., Lawson L., et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One 2008, 3(8):e2858.
25. Azzurri A., Sow O.Y., Amedei A., Bah B., Diallo S., Peri G., et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005 Jan, 7(1):1-8.
26. Hong J.Y., Lee H.J., Kim S.Y., Chung K.S., Kim E.Y., Jung J.Y., et al. Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment. J Infect 2014 Mar, 68(3):252-258.
27. Mihret A., Abebe M., Bekele Y., Aseffa A., Walzl G., Howe R. Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients. BMC Infect Dis 2014, 14:125.
28. Riou C., Perez P.B., Roberts L., Ronacher K., Walzl G., Manca C., et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One 2012, 7(5):e36886.
29. Kabeer B.S., Raja A., Raman B., Thangaraj S., Leportier M., Ippolito G., et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 2011, 11:135.
30. Dyrhol-Riise A.M., Gran G., Wentzel-Larsen T., Blomberg B., Haanshuus C.G., Morkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 2010, 10:57.
31. Pullar N.D., Steinum H., Tonby K., Heggelund L., Leiva R.A., Ofstad R., et al. Low prevalence of positive interferon-gamma tests in HIV-positive long-term immigrants in Norway. Int J Tuberc Lung Dis 2014 Feb, 18(2):180-187.
32. Feruglio S.L., Tonby K., Kvale D., Dyrhol-Riise A.M. Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection. Clin Exp Immunol 2014 Oct 14.
33. Nasjonalt folkehelseinstitutt Tuberkuloseveilederen (Norwegian, Guidelines for tuberculosis) 2014, Available:, [accessed 23.05.14]. http://www.fhi.no/publikasjoner-og-haandboker/tuberkuloseveilederen.
34. Sandanger O., Ryan L., Bohnhorst J., Iversen A.C., Husebye H., Halaas O., et al. IL-10 enhances MD-2 and CD14 expression in monocytes and the proteins are increased and correlated in HIV-infected patients. J Immunol 2009 Jan 1, 182(1):588-595.
35. Punyadeera C., Schneider E.M., Schaffer D., Hsu H.Y., Joos T.O., Kriebel F., et al. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J Emerg Trauma Shock 2010 Jan, 3(1):26-35.
36. Askarieh G., Alsio A., Pugnale P., Negro F., Ferrari C., Neumann A.U., et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010 May, 51(5):1523-1530.
37. Keating S.M., Golub E.T., Nowicki M., Young M., Anastos K., Crystal H., et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011 Sep 24, 25(15):1823-1832.
38. Stylianou E., Aukrust P., Bendtzen K., Muller F., Froland S.S. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol 2000 Mar, 119(3):479-485.
39. Juffermans N.P., Verbon A., van Deventer S.J., van D.H., Belisle J.T., Ellis M.E., et al. Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis: a possible role for mycobacterial lipoarabinomannan. Infect Immun 1999 Aug, 67(8):4295-4297.
40. Liovat A.S., Rey-Cuille M.A., Lecuroux C., Jacquelin B., Girault I., Petitjean G., et al. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 2012, 7(10):e46143.
41. Hong J.Y., Jung G.S., Kim H., Kim Y.M., Lee H.J., Cho S.N., et al. Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis 2012 Dec, 16(12):e855-e859.
42. Chen D.Y., Shen G.H., Chen Y.M., Chen H.H., Lin C.C., Hsieh C.W., et al. Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis. Int J Tuberc Lung Dis 2011 Feb, 15(2):192-200.
43. Chen Y.C., Chin C.H., Liu S.F., Wu C.C., Tsen C.C., Wang Y.H., et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. Dis Markers 2011, 31(2):101-110.
44. Blauenfeldt T., Heyckendorf J., Graff J.S., Lange C., Drabe C., Hermansen T.S., et al. Development of a one-step probe based molecular assay for rapid immunodiagnosis of infection with M. tuberculosis using dried blood spots. PLoS One 2014, 9(9):e105628.
45. Drabe C.H., Blauenfeldt T., Ruhwald M. ELISA-based assay for IP-10 detection from filter paper samples. Methods Mol Biol 2014, 1172:27-37.
46. Aabye M.G., Eugen-Olsen J., Werlinrud A.M., Holm L.L., Tuuminen T., Ravn P., et al. A simple method to quantitate IP-10 in dried blood and plasma spots. PLoS One 2012, 7(6):e39228.
47. Aabye M.G., Latorre I., Diaz J., Maldonado J., Mialdea I., Eugen-Olsen J., et al. Dried plasma spots in the diagnosis of tuberculosis: IP-10 release assay on filter paper. Eur Respir J 2013 Aug, 42(2):495-503.
48. Cannas A., Calvo L., Chiacchio T., Cuzzi G., Vanini V., Lauria F.N., et al. IP-10 detection in urine is associated with lung diseases. BMC Infect Dis 2010, 10:333.
49. Petrone L., Chiacchio T., Vanini V., Petruccioli E., Cuzzi G., Di G.C., et al. High urine IP-10 levels associate with chronic HCV infection. J Infect 2014 Jun, 68(6):591-600.
50. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008 Oct, 8(10):601-611.
51. Wang S., Diao N., Lu C., Wu J., Gao Y., Chen J., et al. Evaluation of the diagnostic potential of IP-10 and IL-2 as biomarkers for the diagnosis of active and latent tuberculosis in a BCG-vaccinated population. PLoS One 2012, 7(12):e51338.
52. Juffermans N.P., Verbon A., van Deventer S.J., van D.H., Speelman P., van der Poll T. Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Am J Respir Crit Care Med 1998 Apr, 157(4 Pt 1):1328-1331.
53. Mantovani A., Garlanda C., Bottazzi B. Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003 Jun 1, 21(Suppl. 2):S43-S47.